IGC Pharma received U.S. Patent No. 12,491,200 on December 19 2025 for a microdose‑based cannabinoid formulation that targets the frequency and severity of symptoms in stuttering and Tourette’s syndrome. The patent protects a novel delivery method that aims to provide therapeutic benefit while minimizing psychoactive effects, a key differentiator in the cannabinoid space.
The new patent unlocks a market that was valued at roughly $2.71 billion for Tourette’s syndrome treatments and $4.3 billion for stuttering therapies in 2025, with forecasts of $3.48 billion and $5.0 billion respectively by 2030. If IGC can advance the formulation through clinical development, the company could tap into a patient base of tens of millions worldwide, creating a substantial revenue opportunity beyond its Alzheimer’s pipeline.
Despite the patent milestone, IGC Pharma’s financials remain under pressure. Recent quarterly reports show significant net losses and negative operating margins, and the company’s Altman Z‑score indicates potential distress. The patent does not immediately generate cash flow, and investors are focused on the company’s ability to manage its cash burn while advancing more mature assets such as IGC‑AD1.
CEO Ram Mukunda emphasized that the new IP “strengthens our leadership position in cannabinoid‑based neurological therapeutics and expands our pipeline opportunities well beyond Alzheimer’s.” He added that the patent protects methods to reduce symptom severity in conditions with limited treatment options, underscoring the company’s strategy to diversify its therapeutic focus.
Market reaction to the patent announcement was muted. Shares fell 9.28 % on the day, reflecting investor concern over IGC’s ongoing financial challenges and the long development timeline for the new indication. Analysts noted that while the patent is a positive step, it does not offset the company’s current profitability issues or the uncertainty surrounding clinical progress.
The patent positions IGC to pursue licensing or partnership opportunities in the stuttering and Tourette’s markets, potentially generating future revenue streams. However, the company will need to secure additional funding and demonstrate clinical efficacy before the IP can translate into commercial success. Investors will likely monitor IGC’s progress on both its Alzheimer’s lead and the new cannabinoid platform to assess the overall impact on the company’s valuation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.